MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced that it has promoted Eric Risser to Chief Operating Officer, as of February 22.
ROCKVILLE, MD, Feb. 28, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced today that it has promoted Eric Risser to Chief Operating Officer, as of February 22.
Mr. Risser joined MacroGenics in 2009 and has played an instrumental leadership role in sourcing, structuring and negotiating the company’s collaboration partnerships and has been responsible for the Company’s alliance and program management and new product planning functions. He was previously promoted to Senior Vice President, Business Development and Portfolio Management and Chief Business Officer in September 2016. Prior to joining MacroGenics, Mr. Risser held the position of Senior Director, Business Development in the pharmaceutical group at Johnson & Johnson, where he worked from 2003 to 2009. Mr. Risser holds a B.A. from Yale University and an M.B.A. from Stanford University.
“Eric has been an effective and strategic leader within MacroGenics. The creation of this new position reflects our confidence in his judgment, ability and leadership to more efficiently advance our product candidates and create value for our shareholders,” said Scott Koenig, M.D., Ph.D., President and Chief Executive Officer of MacroGenics. “We have benefited greatly from Eric’s contributions to date and we are delighted to recognize the broader role he will play as MacroGenics continues to expand and execute on our mission to develop breakthrough biologics that represent life-changing medicines for patients.”
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics’ technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company’s website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development of the Company’s therapeutic candidates, expected timing of results from clinical trials, discussions with regulatory agencies, commercial prospects of or product revenues from MARGENZA, milestone or opt-in payments from the Company’s collaborators, the Company’s anticipated milestones and other statements containing the words “subject to”, “believe”, “anticipate”, “plan”, “expect”, “intend”, “estimate”, “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks that MARGENZA revenue, expenses and costs may not be as expected, risks relating to MARGENZA’s market acceptance, competition, reimbursement and regulatory actions, the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company’s product candidates and other risks described in the Company’s filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.
CONTACTS: Chris James, M.D., Vice President, Investor Relations & Corporate Communications Jim Karrels, Senior Vice President, CFO 1-301-251-5172, info@macrogenics.com
